SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies
Sarepta is seeking full approval for Amondys 45 and Vyondys 53 in Duchenne muscular dystrophy.
Stocktwits
More News
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology
XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.
Stocktwits
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease.
Stocktwits
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle
The U.S. Court of Appeals for the D.C. Circuit said federal law prevents judges from reviewing Medicare’s decision to include certain kidney drugs in the dialysis payment bundle.
Stocktwits
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes
The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26.
Stocktwits
SLS Stock Up 13% As Executive Severance Updates Reignite Buyout Speculation
The company updated the severance agreements for three of its top executives, including the CEO.
Stocktwits
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy
Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader commercial coverage.
Stocktwits
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
Absci Corporation said that its drug ABS-201 was well-tolerated and showed a long-lasting presence in the body in a clinical trial.
Stocktwits
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019
VK3019 targets amylin and calcitonin receptors, which play roles in appetite control, feelings of fullness and metabolism.
Stocktwits
LLY Stock Rides Trump Spotlight: President Touts Eli Lilly’s $3.5B Factory As Weight-Loss Pill Plans Go Global
Trump said the new “state-of-the-art” facility would create over 1,000 jobs.